MedTrace Logo

Efficacy and Safety Study of Isuzinaxib in Subjects With DKD

NCT06962098 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 186

Last updated 2025-07-18

No results posted yet for this study

Summary

This study is a multicenter, double-blinded, randomized, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, PK, and efficacy of Isuzinaxib compared with placebo in subjects with DKD.

Conditions

  • Diabetic Kidney Disease (DKD)

Interventions

DRUG

Isuzinaxib

Oral dosing regimen once daily

DRUG

Placebo

Oral dosing regimen once daily

Sponsors & Collaborators

  • Aptabio Therapeutics, Inc.

    lead INDIV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-26
Primary Completion
2027-06-30
Completion
2028-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06962098 on ClinicalTrials.gov